Neuraxis, Inc.
Compare this stock
NRXS Stock Report Card
$
15%
Performance
Score:
10/100
NRXS returned -56.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Profit
Score:
10/100
Out of the last 7 quarters, NRXS has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
36/100
NRXS has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.
Neuraxis, Inc. Summary
Healthcare
Biotechnology
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
NRXS scored poorly on our reportcard. Here are some similar companies and how they performed.
